Super-Sized flu vaccine shows promise for seniors
NCT ID NCT04024228
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times
Summary
This study tested a high-dose flu vaccine (QIV-HD) against the standard dose in over 1,500 adults aged 60 and older. The goal was to see if the high-dose version triggers a stronger immune response against four flu strains. Researchers measured antibody levels 28 days after vaccination and tracked safety. If it works, it could offer better protection for older adults who are more vulnerable to severe flu.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number 0560001
Ghent, BE-9000, Belgium
-
Investigational Site Number 0560002
Wilrijk, 2610, Belgium
-
Investigational Site Number 2500001
Gières, 38610, France
-
Investigational Site Number 2500003
Pierre-Bénite, 69495, France
-
Investigational Site Number 2500004
Paris, 75014, France
-
Investigational Site Number 2760001
Essen, 45136, Germany
-
Investigational Site Number 2760002
Oldenburg in Holstein, 23758, Germany
-
Investigational Site Number 2760003
Berlin, 10629, Germany
-
Investigational Site Number 2760004
Berlin, 13347, Germany
-
Investigational Site Number 2760005
Berlin, 10787, Germany
-
Investigational Site Number 3800001
Genova, IT-16132, Italy
-
Investigational Site Number 3800003
Palermo, 90127, Italy
-
Investigational Site Number 5280001
Utrecht, 3584 CX, Netherlands
-
Investigational Site Number 6160001
Dębica, 39-200, Poland
-
Investigational Site Number 6160002
Wola, 43-225, Poland
-
Investigational Site Number 6160003
Siemianowice Śląskie, 41-103, Poland
-
Investigational Site Number 6160004
Wroclaw, 50-452, Poland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
High-dose quadrivalent influenza vaccine (QIV-HD)
What this could lead to
If successful, this could mean a more effective flu shot for older adults, reducing flu-related hospitalizations and complications.
What could go wrong
This trial is completed and results are available, but the high-dose vaccine may cause more local side effects like soreness. Superior immune response does not guarantee fewer infections in real-world settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.